<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="data-paper"><?DTDIdentifier.IdentifierValue -//NPG//DTD XML Article//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName NPG_XML_Article.dtd?><?SourceDTD.Version 2.7.10?><?ConverterInfo.XSLTName nature2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Data</journal-id><journal-id journal-id-type="iso-abbrev">Sci Data</journal-id><journal-title-group><journal-title>Scientific Data</journal-title></journal-title-group><issn pub-type="epub">2052-4463</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5663207</article-id><article-id pub-id-type="pii">sdata2017167</article-id><article-id pub-id-type="doi">10.1038/sdata.2017.167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Data Descriptor</subject></subj-group></article-categories><title-group><article-title>A dataset quantifying polypharmacy in the United
States</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>Katie J.</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Nigam H.</given-names></name><xref ref-type="aff" rid="a1">1</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9385-7158</contrib-id></contrib><aff id="a1"><label>1</label><institution>Stanford Center for Biomedical Informatics
Research</institution>, Stanford,
California, CA 94305,
<country>USA</country></aff></contrib-group><author-notes><corresp id="c1"><label>a</label>
K.Q. (email: <email>katiequinn@stanford.edu</email>).</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>4</volume><elocation-id>170167</elocation-id><history><date date-type="received"><day>18</day><month>08</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>09</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017, The Author(s)</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p><bold>Open Access</bold> This article is licensed under a Creative
Commons Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were
made. The images or other third party material in this article are included
in the article&#x02019;s Creative Commons license, unless indicated
otherwise in a credit line to the material. If material is not included in
the article&#x02019;s Creative Commons license and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a copy
of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> The Creative
Commons Public Domain Dedication waiver <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link> applies to
the metadata files made available in this article.
</license-p></license></permissions><abstract><p>Polypharmacy is increasingly common in the United States, and contributes to the
substantial burden of drug-related morbidity. Yet real-world polypharmacy
patterns remain poorly characterized. We have counted the incidence of
multi-drug combinations observed in four billion patient-months of outpatient
prescription drug claims from 2007&#x02013;2014 in the Truven Health
MarketScan&#x000ae; Databases. Prescriptions are grouped into discrete windows
of concomitant drug exposure, which are used to count exposure incidences for
combinations of up to five drug ingredients or ATC drug classes. Among patients
taking any prescription drug, half are exposed to two or more drugs, and 5% are
exposed to 8 or more. The most common multi-drug combinations treat
manifestations of metabolic syndrome. Patients are exposed to unique drug
combinations in 10% of all exposure windows. Our analysis of multi-drug exposure
incidences provides a detailed summary of polypharmacy in a large US cohort,
which can prioritize common drug combinations for future safety and efficacy
studies.</p></abstract><kwd-group kwd-group-type="npg.subject"><title>Subject terms</title><kwd>Data integration</kwd><kwd>Data mining</kwd><kwd>Drug therapy</kwd><kwd>Pharmacology</kwd></kwd-group></article-meta></front><body><sec disp-level="1"><title>Background and Summary</title><p>Concomitant use of multiple prescription drugs (&#x02018;polypharmacy&#x02018;) is
increasingly common, with 10% of the population<sup><xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref></sup> and 30% of older
adults in the United States taking five or more drugs simultaneously<sup><xref ref-type="bibr" rid="b1">1&#x02013;3</xref></sup>. Similarly high
prevalence is reported in other countries (e.g., the United Kingdom<sup><xref ref-type="bibr" rid="b4">4</xref></sup>, Sweden<sup><xref ref-type="bibr" rid="b5">5</xref></sup>, China<sup><xref ref-type="bibr" rid="b6">6</xref></sup>, Brazil<sup><xref ref-type="bibr" rid="b7">7</xref></sup>, and
India<sup><xref ref-type="bibr" rid="b8">8</xref></sup>. The prevalence of
polypharmacy is driven by high rates of comorbidities (in the United States in 2012,
26% of all adults, and 61% of adults over 65 years of age had two or more chronic
conditions<sup><xref ref-type="bibr" rid="b9">9</xref></sup>), and
exacerbated by clinical practices enabling overprescription and insufficient
monitoring<sup><xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b11">11</xref></sup>. Drug-related morbidity has become
a substantial healthcare burden: in the United States, adverse drug reactions are
prevalent (causing 4 hospitalizations per 1000 people each year<sup><xref ref-type="bibr" rid="b10">10</xref></sup>), serious (among top 10 common
causes of death<sup><xref ref-type="bibr" rid="b12">12</xref></sup>), and expensive
(with associated annual costs estimated at US$30billion<sup><xref ref-type="bibr" rid="b13">13</xref></sup> to US$180billion<sup><xref ref-type="bibr" rid="b14">14</xref></sup>).</p><p>Exposure to multiple drugs puts patients at additive risk of each single
drug&#x02019;s potential adverse outcomes. In a study of an elderly cohort, the
strongest predictor of a potentially harmful medication was the number of drug
prescriptions<sup><xref ref-type="bibr" rid="b15">15</xref></sup>. But drugs
can also interact to increase risk beyond &#x02018;the sum of the parts&#x02019;,
either by canceling an intended drug action, enhancing existing risks, or creating
new risks. It&#x02019;s estimated that over 20% of adverse drug reactions are due to
underlying drug interactions<sup><xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref></sup>, and that risk of drug interaction
increases with the number of drugs taken<sup><xref ref-type="bibr" rid="b18">18</xref></sup>. However, despite increasing awareness of morbidity related
to polypharmacy, multi-drug exposure patterns remain poorly characterized.</p><p>Insurance claims records enable analysis of prescription practices in a large patient
cohort, even for drug regimens that would be rare in smaller cohorts. The 21st
Century Cures Act, enacted in December 2016, recognizes the value of, and mandates
the use of, observational patient-experience data, such as insurance claims, for
drug surveillance<sup><xref ref-type="bibr" rid="b19">19</xref></sup>. The relative
strengths of insurance claims for characterizing population-level drug use are that
data reflect prescriptions that are actually dispensed to the patient, and capture
prescription information across very large cohorts. As for most sources of drug use
data, whether patients actually ingested the drugs remains a limitation.</p><p>Here, we publish a dataset of multi-drug exposure incidence in a large insured cohort
in the United States, both in terms of drug ingredients and drug classes. We analyze
outpatient prescription drug claims from the Truven Health MarketScan&#x000ae;
Research Databases, which contain health coverage records for over 100 million
employees, dependents, and retirees in the United States from 2007&#x02013;2014,
amounting to over 4 billion months of patient observation. <xref ref-type="table" rid="t1">Table 1</xref> summarizes relevant metrics of the database. Prior to
our work, Sutherland <italic>et al.</italic> have reported on co-prescription trends
using self-reported data from a small but nationally-representative cohort of 10,000
NHANES participants. The frequency of some drug-pair exposures among elderly
participants was also reported<sup><xref ref-type="bibr" rid="b2">2</xref></sup>. To
our knowledge, ours is the first study to quantify the incidence of specific
combinations of more than two drugs. <xref ref-type="fig" rid="f1">Figure 1</xref>
summarizes our workflow of processing prescription drug claims into discrete
exposure time-windows, and then counting concomitant drug exposures for drug
ingredients and ATC-II drug classes.</p><p>This dataset will benefit researchers who study multi-drug safety or efficacy. The
most common multi-drug combinations can be prioritized for subsequent studies of
multi-drug safety or efficacy. As a side benefit, by mapping drugs to disease based
on indications, the dataset can also provide a summary of comorbidities that drive
the observed prescription trends.</p><p>This dataset will also benefit practitioners by enabling risk stratification of
patients based on the multi-drug combinations they are on; for example, the dataset
enables analyses identifying associations of specific drug combinations with health
outcomes (such as emergency department visits), which could enable patient risk
stratification at the time of medication reconciliation.</p><p>Ultimately combined analyses spanning both safety and risk stratification will enable
systematic progress towards safe polypharmacy. With roughly 40 million individuals
experiencing polypharmacy in the US and as many as 10% of all adults worldwide, the
existence of such datasets is crucial for a data-driven quantification of which drug
combinations are risky.</p></sec><sec disp-level="1"><title>Methods</title><sec disp-level="2"><title>Data source</title><p>Prescription drug claim data were derived from the Truven Health MarketScan 2007
to 2014 Commercial Claims and Encounters and Medicare Supplemental and
Coordination of Benefits Databases, which were accessed via the Stanford Center
for Population Health Sciences Data Core. Further details about the Data Core
and its operating procedures are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://med.stanford.edu/phs/phs-data-center.html">http://med.stanford.edu/phs/phs-data-center.html</ext-link>. These
databases represent the health services of approximately 100 million employees,
dependents, and retirees in the United States with primary or Medicare
supplemental coverage through privately insured fee-for-service,
point-of-service, or capitated health plans. The Commercial Claims and
Encounters, and Medicare Supplemental and Coordination of Benefits populations
comprise 90 and 10% of the total cohort respectively, with a mean age of 33 and
73 years and gender fraction of 49 and 45% male, creating a combined cohort with
a mean age of 37 years and 48% male. Patients are observed for a median of 29
months. We analyzed the outpatient prescription drug claims of 150 million
patients over 4.3 billion months of patient enrollment. We focus on outpatient
prescriptions since 90% of all prescriptions are in the outpatient
setting<sup><xref ref-type="bibr" rid="b20">20</xref></sup>, and
inpatient drug treatment patterns differ substantially.</p></sec><sec disp-level="2"><title>Drug list curation and drug mapping</title><p>We curated a set of 1429 drugs, defined by RxNORM ingredient level, by beginning
with the 1165 drug ingredients occurring in all of DrugBank, RxNORM, and UMLS
(previously curated in our lab<sup><xref ref-type="bibr" rid="b21">21</xref></sup>), adding drug ingredients occurring commonly in the Truven
Health MarketScan Databases, and removing vaccines, and vitamins and minerals
(which are more often obtained over-the-counter than by prescription).</p><p>Of this set of 1429 drug ingredients, 864 occur in the Truven Health MarketScan
Database prescription claims. Drugs are identified in prescriptions using
National Drug Codes (NDCs). We built a mapping of NDCs to RxNORM-defined drug
ingredients using the NLM&#x02019;s RxMix API to match on strings containing
drug names, first with strict matching (which maps the majority of NDCs with
very low error), then with approximate string matching (which maps the remaining
NDCs but requires manual validation of string matches).</p><p>Combination drugs (e.g., Norco) count as exposure to each drug ingredient (e.g.,
acetaminophen and hydrocodone). The approximate drug cost per day was calculated
as the median payment-per-days-supply for all patient orders of that drug. Drugs
are also classified by Anatomical Therapeutic Chemical (ATC) class at the second
level (&#x02018;therapeutic main group&#x02019;), by mapping RxNORM identifiers
to ATC codes. The 864 unique drug ingredients in the dataset map to 79 unique
second-level ATC classes.</p></sec><sec disp-level="2"><title>Extracting discrete exposure windows from drug prescriptions</title><p>To count concomitant drug exposures from prescription claims, we first scanned
drug prescriptions into discrete exposure windows. We defined exposure periods
as non-overlapping 30-day windows. We selected a 30-day window because it is the
most common prescription duration, and thus a natural timescale for
prescriptions. A patient is considered exposed to a drug starting from the date
the prescription and for the duration of the days-of-supply. If any of those
days overlap with a window, the patient is considered exposed in that window
(<xref ref-type="fig" rid="f2">Fig. 2a</xref>). This method is
computationally efficient and provides a good approximation of concomitant
exposure.</p><p>As a known limitation, the method overestimates exposures, and thus concomitant
exposures, if a patient does not take the prescription for its full duration. As
shown in <xref ref-type="fig" rid="f2">Fig. 2b</xref>, non-overlapping windows
introduce error when either: 1) non-concomitant prescriptions are separated by
less than 30-&#x02009;days yet both overlap with a particular exposure window;
or conversely 2) when prescriptions separated by only a few days fall into
different exposure windows. We create exposure windows using a simple integer
division of patient age-in-days by 30, which is computationally efficient.
However this creates partial windows of observation at the beginning and end of
each patient&#x02019;s eligibility period, with a mean duration of 15-days.
Given that patients are observed for a median of 29 months, this error is
present only in about 5% of windows. However, these 30-day non-overlapping
windows simplify computation, with a low error rate, for the purposes of ranking
the most common multi-drug exposures.</p><p>Using this method, individual patient prescription claims were converted into
drug exposures in discrete windows (<xref ref-type="fig" rid="f1">Fig.
1c</xref>), resulting in 5.1 billion drug exposures. This dataset was then used
to count concomitant drug exposure.</p></sec><sec disp-level="2"><title>Counting concomitant multi-drug exposures</title><p>There are two ways to count multi-drug exposure: exposure to an
&#x02018;exact&#x02019; set of drugs (and no additional drugs), and exposure to
&#x02018;at least&#x02019; a particular set of N-drugs (which may or may not be
taken with additional drugs). Each of these variants captures valuable
information: &#x02018;exact&#x02019; counts quantify the absolute number of
concomitant drug exposures, and how many patients are exposed to a precise sets
of drugs; &#x02018;at least&#x02019; counts are important for knowing all
patients exposed to any given drug combination. See example shown in <xref ref-type="fig" rid="f1">Fig. 1</xref>: Concomitant exposure to drug
ingredients A (class Q), B (class Q), and C (class R) will contribute a count to
A+B+C for &#x02018;exact&#x02019; drug ingredient exposure, and each of A, B, C,
A+B, A+C, B+C, and A+B+C for &#x02018;at least&#x02019; drug exposure.</p><p>This method counted 220 million unique &#x02018;exact&#x02019; drug combinations
exposures, with patients exposed to a median of 2 drugs and 95th-percentile of 8
drugs per window (<xref ref-type="fig" rid="f3">Fig. 3a</xref>). In
approximately 10% of windows, patients were exposed to a unique set of drugs,
never observed elsewhere in the entire database. This is in agreement with a
recent study of treatment pathways that found that 10% of diabetes and
depression patients and almost 25% of hypertension patients received therapeutic
regimens that were unique within a 250-million-large patient cohort<sup><xref ref-type="bibr" rid="b22">22</xref></sup>.</p><p>To count &#x02018;at least&#x02019; multi-drug exposures, we created a drug-based
index to the summarized 220 million &#x02018;exact&#x02019; counts. (This
required much less computation than indexing on the original 5.1 billion
exposure windows.) We then performed an intersect operation for each
&#x02018;at-least&#x02019; drug combination of interest. Counting all possible
drug combinations is infeasible, and unnecessary since most combinations are
never observed. The challenge was to create a list of N-drug combinations likely
to have high concomitant exposures. We achieved this with a
&#x02018;greedy&#x02019; approach of constructing N-drug combinations from
N-minus-1 subset drug combinations observed in at least 1000 exposure windows,
for each of N=2, 3, 4 and 5 drugs.</p><p>An additional metric of interest is the extent to which drug combinations are
concomitant beyond what would be expected by chance, given their marginal
frequencies. Drug combinations&#x02019; overrepresentation was defined as the
ratio of the observed-to-expected drug combination incidence in two ways: first
(for N&#x0003e;1) based on single-drug frequencies, which gives the overall
overrepresentation; and second (for N&#x0003e;2) based on the minimum of each of
N permutations of (N-1)+1 drug subsets, which is greater than the single-drug
overrepresentation, and gives the overrepresentation of the drug combination
beyond its subsets. (As an example, the co-incidence of drugs A+B+C is compared
to the incidence expected by chance based on the incidences of drugs A+B and C,
A+B and B, and B+C and A. The smallest overrepresentation is reported. The
second method is only reported for N&#x0003e;2, because the two methods are
equivalent for N=2.)</p><p>We repeated these computations of &#x02018;exact&#x02019; and &#x02018;at
least&#x02019; exposure counts, and their overrepresentation, for the 79
second-level ATC drug classes. Second-level ATC drug class names were extracted
from the website of the WHO Collaborating Centre for Drug Statistics
Methodology. Though one drug ingredient can map to multiple ATC classes, we
count only the primary class. Continuing the example in <xref ref-type="fig" rid="f1">Fig. 1</xref>, concomitant exposure to drugs from classes Q and R
would be counted as (iii) Q+R for &#x02018;exact&#x02019; drug class exposure,
and (iv) Q, R, and Q+R for &#x02018;at least&#x02019; drug class exposure. (Note
that drug classes are counted only once, even if a patient is taking two or more
drugs from a particular class). This calculation yielded 39 million unique exact
drug class exposures, with patients exposed to a median of 2 and 95th-percentile
of 7 drug classes per window (<xref ref-type="fig" rid="f3">Fig. 3b</xref>).</p></sec><sec disp-level="2"><title>Code availability</title><p>Code used to generate the dataset is available on a public github repository
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/katieq/QuantifyingPolypharmacy">https://github.com/katieq/QuantifyingPolypharmacy</ext-link>). To avoid
disclosing the format of the Truven Health Marketscan Databases, the code begins
at the step of analyzing prescription data extracted into a data-frame with
columns for a patient identifier, drug identifier, age of prescription, and days
of supply.</p></sec></sec><sec disp-level="1"><title>Data Records</title><p>The dataset of exposure counts for drug and drug-class combinations is publicly
available online at Dryad (Data Citation 1)
in 12 tab-delimited data files and a README.txt file. The tab-delimited data files
are outlined below and in <xref ref-type="table" rid="t2">Table 2</xref>. The
accompanying README.txt file contains filenames and descriptions of file contents.
Data files can be accessed directly by their associated URLs, for example by reading
into R with the readr package&#x02019;s read_tsv function. <xref ref-type="table" rid="t2">Table 2</xref> summarizes attributes of the underlying patient claims
data in the 2007&#x02013;2014 Truven Health MarketScan Commercial and Medicare
Supplemental Databases.</p><sec disp-level="2"><title>Data Record 1: Drug ingredient combination exposure counts</title><p>Data Record 1 contains the exposure incidences for the most common combinations
of <italic>N=1-to-5</italic> drugs in five files, with one row per combination.
All single drugs (N=1) and drug pairs (N=2) are included; for N=3-to-5, drug
combinations with at least 10,000 exposure counts are included. Exposure counts
below 100 patient-windows are reported as &#x02018;&#x0003c;100&#x02019; to
protect patient privacy. Each row contains <italic>N+5</italic> tab-delimited
columns comprising: the name for each drug ingredient, the count of windows with
concomitant exposure to this drug combination, potentially concomitant with
additional drugs (<italic>atleast_exposure_count</italic>), the count of windows
with concomitant exposure to this drug combination and no additional drugs
(<italic>exact_exposure_count</italic>), the ratio of the two previous
columns (<italic>fraction_exact</italic>), the ratio of the
<italic>atleast_exposure_count</italic> to the total number of observed
windows with any prescription (<italic>fraction_all_windows</italic>),
overrepresentation beyond expected based on marginal frequencies of single drugs
(<italic>observe_per_expect_1s</italic>) and (N-1)+1 drug subsets
(<italic>observe_per_expect_N1</italic>), and an estimate of the daily cost
of the drug combination (<italic>estimate_drug_combo_cost_per_day</italic>).</p></sec><sec disp-level="2"><title>Data Record 2: Drug class combination exposure counts</title><p>The contents of Data Record 2 are equivalent to Data Record 1, but for level-II
ATC drug classes instead of drug ingredients. The record also contains five
files for combinations of <italic>N=1-to-5</italic> drug classes, with one row
per combination. As for Data Record 1, all single drug class (N=1) and drug
class pairs (N=2) are included, and drug class combinations with at least 10,000
exposure counts are included for N=3-to-5; exact exposure counts of less than
100 are reported as &#x02018;&#x0003e;100&#x02019;. Columns are equivalent to
Data Record 1&#x02019;s, with drug class names replacing drug ingredient names.
However daily cost can not be calculated at the drug class level.</p></sec><sec disp-level="2"><title>Data Record 3: Drug mappings</title><p>Data Record 3 contains two tab-delimited files containing the list of 1429 drug
ingredients and 93 corresponding ATC level-2 drug classes considered in this
study. The drug ingredient file contains one drug per row sorted alphabetically
by drug ingredient name, with five columns for the drug ingredient name, RxNorm
CUI number, UMLS CUI, Drug Bank ID, ATC code, second-level ATC drug class name,
and estimated median cost per day. The drug class mappings file contains one ATC
level-2 drug class per row sorted alpha-numerically by ATC class, with two
columns for the ATC code and name. (Thus the ATC level-2 class names in the drug
ingredient file are redundant, but included for convenience).</p></sec></sec><sec disp-level="1"><title>Technical Validation</title><p>We validated our method in three ways. First, we compared our computational
method&#x02019;s results to manual counting, by reading the dates and days-supply
for a random sample of ten patients&#x02019; 260 drug prescriptions. The counts of
concomitant drug exposures matched perfectly, indicating that our method does indeed
accurately extract concomitant drug exposures as intended without errors in
arithmetic.</p><p>Second, we conducted a sensitivity analysis on the duration of the discrete exposure
window, by counting concomitant drug exposures in a random sample of 10,000 patients
with an exposure window of 10, 20, 30, 40, 50, 60, and 90 days. Since all
prescriptions are considered &#x02018;exposures&#x02019; for the entire duration of
the window, longer windows slightly increase the mean drug exposure counts (average
drug exposure count is 3.1, 3.2 and 3.8 for a 10-, 30-, or 90-day window
respectively), and thus increase the relative incidence (i.e., ranking) of
prescriptions with short-durations (e.g., antibiotics or short-term pain relief).
Thus the choice of exposure window duration <italic>does</italic> affect the Data
Records. Therefore we set the window duration equal to the most common prescription
duration. Prescriptions in this claims database are most often for 30 days (50% of
all prescriptions), with about 20% for 10 or fewer days. Thus a 30-day window is an
appropriate timescale to capture changes in drug exposures.</p><p>Finally, we tested the sensitivity to cohort size, by comparing the drug combination
incidence ranking obtained using the entire Truven Health MarketScan cohort
(approximately 100 million patients) to a random sample of 100,000 (1e5) patients,
and 1,000,000 (1e6) patients. As expected, analysis of smaller cohorts obtains a
similar <italic>ranking</italic> of the common drug combinations, but inaccurately
estimates the incidence, and thus the ranking, of rare drug combinations. In
addition, smaller cohorts overestimate the patients exposed to unique drug
combinations, never observed elsewhere in the database: In the complete cohort, 10%
of drug combinations are observed only once, but in a cohort of 1e5 patients, that
fraction is 20%. Thus while smaller cohorts are sufficient to rank the incidence of
common drug combinations, a large patient cohort is required to accurately estimate
the incidence of drug combinations.</p><sec disp-level="2"><title>Limitations</title><p>The accuracy of this dataset as a summary of multi-drug exposure incidences in
the United States is limited to some extent by the underlying data source and
our method of computation. The Truven Health MarketScan Research Databases
cohort is commercial claims, and not a fully representative sample of the United
States population. We examine drug exposure based on filled prescriptions, but
patients may take none or only a fraction of the dispensed drugs. Since there is
bias on adherence <italic>between</italic> drugs, this will introduce bias in
the resulting single drug and drug combination incidences. However, billing data
from filled prescriptions are more accurate than alternative sources, such as
doctor&#x02019;s notes or prescription orders that may go unfilled.</p><p>We only observe and analyze prescription drugs, but over-the-counter drugs and
supplements contribute a significant portion of total drug exposures<sup><xref ref-type="bibr" rid="b23">23</xref></sup>. Though patient surveys can
offer information about exposure to over-the-counter drugs and supplements, they
rely on patient memory, and lack the cohort size and accuracy of prescription
records.</p><p>Our method scans prescription drug claims according to 30-day exposure windows.
Shorter or longer exposure windows would increase or decrease apparent
multi-drug exposures respectively. The size of the exposure window affects drug
combinations&#x02019; relative incidence (i.e., ranking), with longer windows
increasing the apparent incidence of combinations including drugs with short
prescription durations (e.g., antibiotics or short-term pain relief). However
the rankings are agnostic to exposure window duration with our choice of a
window of 30-days, to match the days-of-supply of the majority of
prescriptions.</p><p>Finally, our analysis uses all data from 2007&#x02013;2014, ignoring the likely
non-stationarity of prescription patterns<sup><xref ref-type="bibr" rid="b24">24</xref></sup> (as suggested by the increase in prevalence of
polypharmacy from 8% to 15% between the 1999&#x02013;2000 and 2011&#x02013;2012
NHANES surveys<sup><xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b25">25</xref></sup>). Nonetheless, our multi-drug
exposure dataset provides a ranking of common concomitant prescription drug
exposures for a large population in the United States.</p></sec></sec><sec disp-level="1"><title>Usage Notes</title><p>This summary of multi-drug prescription patterns in a large cohort enables further
analysis of the trends, safety, or efficacy of multi-drug use.</p><sec disp-level="2"><title>Prioritize common multi-drug combinations for adverse event association
analysis</title><p>The common multi-drug combinations identified here can now be prioritized for
analysis of association with adverse health outcomes. An example illustrating
this use case is identifying which of the common 3-drug combinations in Data
Record 1 are most overrepresented in the 30-days prior to Emergency Department
visits (<xref ref-type="table" rid="t3">Table 3</xref>). It is important to note
that this association tells us nothing about causation, but merely identifies
drug combinations taken at increased rates by patients prior to ED visits. Thus,
as indicators of patients&#x02019; health state, multi-drug combinations could
potentially be used to identify patients at risk of an ED visit in the
near-future. Similar association analysis can be completed with any desirable or
undesirable outcome, in any cohort of interest, for various study designs.</p></sec><sec disp-level="2"><title>Identify drugs used concomitantly with a given drug of interest</title><p>This dataset can be used to profile the common co-exposures for any drug
ingredient or class of interest. <xref ref-type="table" rid="t4">Table 4</xref>
shows this analysis for the first line diabetes drug metformin and the opioid
oxycodone. The summary was obtained by extracting rows containing metformin or
oxycodone from the 2-drug table of Data Record 1, and normalizing by the total
exposure counts for metformin or oxycodone. Code to perform this analysis for
any drug ingredient or drug class of interest is provided in the R-script
<italic>get_codrugs.R</italic> at the code repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/katieq/QuantifyingPolypharmacy">https://github.com/katieq/QuantifyingPolypharmacy</ext-link>). This could
be repeated for larger drug combinations using the 3-, 4-, or 5-drug tables.</p></sec><sec disp-level="2"><title>Stratify patients by risk of adverse health outcomes, based on prescription
set</title><p>This dataset can now be used to calculate the increased risk of undesirable
health outcomes associated with a particular set of prescriptions. Such a risk
estimate can be used to stratify patients according to risk of future adverse
health events, and then to flag prescription changes that place patients in a
higher risk category, or to identify prescription combination changes that lower
patients&#x02019; risk category. Of course, such risk stratification implies no
causality whatsoever; however, such analyses can provide a succinct report on
the risks experienced by a cohort of similarly-treated patients.</p></sec></sec><sec disp-level="1"><title>Additional information</title><p><bold>How to cite this article:</bold> Quinn, K. J. &#x00026; Shah, N. H. A dataset
quantifying polypharmacy in the United States. <italic>Sci. Data</italic> 4:170167
doi: 10.1038/sdata.2017.167 (2017).</p><p><bold>Publisher&#x02019;s note:</bold> Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.</p></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="d32e22" content-type="local-data"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sdata2017167-isa1.zip"/></supplementary-material></sec></body><back><ref-list content-type="data-citations"><title>Data Citations</title><ref id="d1"><mixed-citation publication-type="data"><source>Dryad Digital Repository</source><name><surname>Quinn</surname><given-names>K. J.</given-names></name><name><surname>Shah</surname><given-names>N. H.</given-names></name><year>2017</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.5061/dryad.sm847">http://dx.doi.org/10.5061/dryad.sm847</ext-link></mixed-citation></ref></ref-list><ack><p>Data for this project were accessed using the Stanford Center for Population Health
Sciences Data Core. The PHS Data Core is supported by a National Institutes of
Health National Center for Advancing Translational Science Clinical and
Translational Science Award (UL1 TR001085) and from Internal Stanford funding. The
content is solely the responsibility of the authors and does not necessarily
represent the official views of the NIH.</p></ack><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Q.</given-names></name>,
<name><surname>Dillon</surname><given-names>C.
F.</given-names></name> &#x00026;
<name><surname>Burt</surname><given-names>V.
L.</given-names></name>
<article-title>Prescription drug use continues to increase: U.S. prescription
drug data for 2007-2008</article-title>. <source>NCHS Data Brief</source>
<fpage>1</fpage>&#x02013;<lpage>8</lpage> (<year>2010</year>).</mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Sutherland</surname><given-names>J.
J.</given-names></name>
<italic>et al.</italic>
<article-title>Co-prescription trends in a large cohort of subjects predict
substantial drug-drug interactions</article-title>. <source>PLoS
ONE</source>
<volume>10</volume>, <fpage>3</fpage> (<year>2015</year>).</mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>Bushardt</surname><given-names>R. L.</given-names></name>,
<name><surname>Massey</surname><given-names>E.
B.</given-names></name>, <name><surname>Simpson</surname><given-names>T. W.</given-names></name>,
<name><surname>Ariail</surname><given-names>J.
C.</given-names></name> &#x00026;
<name><surname>Simpson</surname><given-names>K.
N.</given-names></name>
<article-title>Polypharmacy: misleading, but manageable</article-title>.
<source>Clin. Interv. Aging</source>
<volume>3</volume>, <fpage>383</fpage>&#x02013;<lpage>389</lpage>
(<year>2008</year>).<pub-id pub-id-type="pmid">18686760</pub-id></mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Payne</surname><given-names>R. A.</given-names></name>
<article-title>The epidemiology of polypharmacy</article-title>. <source>Clin.
Med.</source>
<volume>16</volume>, <fpage>465</fpage>&#x02013;<lpage>469</lpage>
(<year>2016</year>).</mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Hovstadius</surname><given-names>B.</given-names></name>,
<name><surname>Hovstadius</surname><given-names>K.</given-names></name>,
<name><surname>Astrand</surname><given-names>B.</given-names></name> &#x00026;
<name><surname>Petersson</surname><given-names>G.</given-names></name>
<article-title>Increasing polypharmacy-an individual-based study of the Swedish
population 2005-2008</article-title>. <source>BMC Clin. Pharmacol.</source>
<volume>10</volume>, <fpage>16</fpage> (<year>2010</year>).<pub-id pub-id-type="pmid">21122160</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>L.</given-names></name>,
<name><surname>Yan</surname><given-names>H.</given-names></name> &#x00026;
<name><surname>Wang</surname><given-names>D.</given-names></name>
<article-title>Polypharmacy and its correlates in village health clinics across
10 provinces of Western China</article-title>. <source>J. Epidemiol.
Community Health</source>
<volume>64</volume>, <fpage>549</fpage>&#x02013;<lpage>553</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">19854749</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="journal"><name><surname>Oliveira</surname><given-names>M. G.</given-names></name>,
<name><surname>Amorim</surname><given-names>W.
W.</given-names></name>, <name><surname>de Jesus</surname><given-names>S. R.</given-names></name>,
<name><surname>Rodrigues</surname><given-names>V.
A.</given-names></name> &#x00026;
<name><surname>Passos</surname><given-names>L.
C.</given-names></name>
<article-title>Factors associated with potentially inappropriate medication use
by the elderly in the Brazilian primary care setting</article-title>.
<source>Int. J. Clin. Pharm.</source>
<volume>34</volume>, <fpage>626</fpage>&#x02013;<lpage>632</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22692715</pub-id></mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Rambhade</surname><given-names>S.</given-names></name>,
<name><surname>Chakarborty</surname><given-names>A.</given-names></name>,
<name><surname>Shrivastava</surname><given-names>A.</given-names></name>,
<name><surname>Patil</surname><given-names>U.
K.</given-names></name> &#x00026;
<name><surname>Rambhade</surname><given-names>A.</given-names></name>
<article-title>A survey on polypharmacy and use of inappropriate
medications</article-title>. <source>Toxicol. Int</source>
<volume>19</volume>, <fpage>68</fpage>&#x02013;<lpage>73</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22736907</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>Ward</surname><given-names>B. W.</given-names></name>,
<name><surname>Schiller</surname><given-names>J.
S.</given-names></name> &#x00026;
<name><surname>Goodman</surname><given-names>R.
A.</given-names></name>
<article-title>Multiple Chronic Conditions Among US Adults: A 2012
Update</article-title>. <source>Prev. Chronic Dis</source>
<volume>11</volume>, <fpage>E62</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24742395</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Shehab</surname><given-names>N.</given-names></name>
<italic>et al.</italic>
<article-title>US Emergency Department Visits for Outpatient Adverse Drug
Events, 2013-2014</article-title>. <source>JAMA</source>
<volume>316</volume>, <fpage>2115</fpage>&#x02013;<lpage>2125</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27893129</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Kessler</surname><given-names>C.</given-names></name>,
<name><surname>Ward</surname><given-names>M.
J.</given-names></name> &#x00026;
<name><surname>McNaughton</surname><given-names>C.
D.</given-names></name>
<article-title>Reducing Adverse Drug Events: The Need to Rethink Outpatient
Prescribing</article-title>. <source>JAMA</source>
<volume>316</volume>, <fpage>2092</fpage>&#x02013;<lpage>2093</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27893112</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Lazarou</surname><given-names>J.</given-names></name>,
<name><surname>Pomeranz</surname><given-names>B.
H.</given-names></name> &#x00026;
<name><surname>Corey</surname><given-names>P.
N.</given-names></name>
<article-title>Incidence of adverse drug reactions in hospitalized patients: a
meta-analysis of prospective studies</article-title>. <source>JAMA</source>
<volume>279</volume>, <fpage>1200</fpage>&#x02013;<lpage>1205</lpage>
(<year>1998</year>).<pub-id pub-id-type="pmid">9555760</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>Sultana</surname><given-names>J.</given-names></name>,
<name><surname>Cutroneo</surname><given-names>P.</given-names></name> &#x00026;
<name><surname>Trifir&#x000f2;</surname><given-names>G.</given-names></name>
<article-title>Clinical and economic burden of adverse drug
reactions</article-title>. <source>J. Pharmacol. Pharmacother</source>
<volume>4</volume>, <fpage>S73</fpage>&#x02013;<lpage>S77</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">24347988</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Ernst</surname><given-names>F. R.</given-names></name> &#x00026;
<name><surname>Grizzle</surname><given-names>A.
J.</given-names></name>
<article-title>Drug-related morbidity and mortality: updating the
cost-of-illness model</article-title>. <source>J. Am. Pharm. Assoc.</source>
<volume>41</volume>, <fpage>192</fpage>&#x02013;<lpage>199</lpage>
(<year>2001</year>).</mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Jir&#x000f3;n</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Trends in Prevalence and Determinants of Potentially
Inappropriate Prescribing in the United States: 2007 to
2012</article-title>. <source>J. Am. Geriatr. Soc</source>
<volume>64</volume>, <fpage>788</fpage>&#x02013;<lpage>797</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27100575</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Magro</surname><given-names>L.</given-names></name>,
<name><surname>Moretti</surname><given-names>U.</given-names></name> &#x00026;
<name><surname>Leone</surname><given-names>R.</given-names></name>
<article-title>Epidemiology and characteristics of adverse drug reactions caused
by drug-drug interactions</article-title>. <source>Expert Opin. Drug
Saf.</source>
<volume>11</volume>, <fpage>83</fpage>&#x02013;<lpage>94</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22022824</pub-id></mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>Strandell</surname><given-names>J.</given-names></name>,
<name><surname>Bate</surname><given-names>A.</given-names></name>,
<name><surname>Lindquist</surname><given-names>M.</given-names></name> &#x00026;
<name><surname>Edwards</surname><given-names>I.
R.</given-names></name>
Swedish, Finnish, Interaction X-referencing
Drug-drug Interaction Database (SFINX Group).
<article-title>Drug-drug interactions - a preventable patient safety
issue?</article-title>
<source>Br. J. Clin. Pharmacol.</source>
<volume>65</volume>, <fpage>144</fpage>&#x02013;<lpage>146</lpage>
(<year>2008</year>).<pub-id pub-id-type="pmid">17635497</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Johnell</surname><given-names>K.</given-names></name> &#x00026;
<name><surname>Klarin</surname><given-names>I.</given-names></name>
<article-title>The relationship between number of drugs and potential drug-drug
interactions in the elderly: a study of over 600,000 elderly patients from
the Swedish Prescribed Drug Register</article-title>. <source>Drug
Saf.</source>
<volume>30</volume>, <fpage>911</fpage>&#x02013;<lpage>918</lpage>
(<year>2007</year>).<pub-id pub-id-type="pmid">17867728</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="other">H.R.34 - 21st Century Cures Act,
<italic>Congress.gov</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/bill/114th-congress/house-bill/34/text">https://www.congress.gov/bill/114th-congress/house-bill/34/text</ext-link>
(<year>2016</year>).</mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Schumock</surname><given-names>G. T.</given-names></name>
<italic>et al.</italic>
<article-title>National trends in prescription drug expenditures and projections
for 2016</article-title>. <source>Am. J. Health. Syst. Pharm.</source>
<volume>73</volume>, <fpage>1058</fpage>&#x02013;<lpage>1075</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27170624</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Iyer</surname><given-names>S. V.</given-names></name>,
<name><surname>Harpaz</surname><given-names>R.</given-names></name>,
<name><surname>LePendu</surname><given-names>P.</given-names></name>,
<name><surname>Bauer-Mehren</surname><given-names>A.</given-names></name> &#x00026;
<name><surname>Shah</surname><given-names>N.
H.</given-names></name>
<article-title>Mining clinical text for signals of adverse drug-drug
interactions</article-title>. <source>J. Am. Med. Inform. Assoc</source>
<volume>21</volume>, <fpage>353</fpage>&#x02013;<lpage>362</lpage>
(<year>2014</year>).<pub-id pub-id-type="pmid">24158091</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Hripcsak</surname><given-names>G.</given-names></name>
<italic>et al.</italic>
<article-title>Characterizing treatment pathways at scale using the OHDSI
network</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>
<volume>113</volume>, <fpage>7329</fpage>&#x02013;<lpage>7336</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27274072</pub-id></mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Qato</surname><given-names>D. M.</given-names></name>,
<name><surname>Wilder</surname><given-names>J.</given-names></name>,
<name><surname>Schumm</surname><given-names>L.
P.</given-names></name>, <name><surname>Gillet</surname><given-names>V.</given-names></name> &#x00026;
<name><surname>Alexander</surname><given-names>G.
C.</given-names></name>
<article-title>Changes in Prescription and Over-the-Counter Medication and
Dietary Supplement Use Among Older Adults in the United States, 2005 vs
2011</article-title>. <source>JAMA Intern. Med.</source>
<volume>176</volume>, <fpage>473</fpage>&#x02013;<lpage>482</lpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">26998708</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Jung</surname><given-names>K.</given-names></name> &#x00026;
<name><surname>Shah</surname><given-names>N.
H.</given-names></name>
<article-title>Implications of non-stationarity on predictive modeling using
EHRs</article-title>. <source>J. Biomed. Inform.</source>
<volume>58</volume>, <fpage>168</fpage>&#x02013;<lpage>174</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26483171</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Kantor</surname><given-names>E. D.</given-names></name>,
<name><surname>Rehm</surname><given-names>C.
D.</given-names></name>, <name><surname>Haas</surname><given-names>J. S.</given-names></name>,
<name><surname>Chan</surname><given-names>A.
T.</given-names></name> &#x00026;
<name><surname>Giovannucci</surname><given-names>E.
L.</given-names></name>
<article-title>Trends in Prescription Drug Use Among Adults in the United States
From 1999-2012</article-title>. <source>JAMA</source>
<volume>314</volume>, <fpage>1818</fpage>&#x02013;<lpage>1831</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26529160</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="COI-statement"><p>The authors declare no competing financial interests.</p></fn></fn-group></back><floats-group><fig id="f1"><label>Figure 1</label><caption><title>Data analysis workflow to generate drug combination exposure incidences from
prescription drug claims.</title><p>Prescription drug claims (<bold>a</bold>) are scanned to create discrete exposure
windows (<bold>c</bold>) for the set of drugs <bold>(b</bold>). These windows
are summarized to produce &#x02018;exact&#x02019; exposure incidences at the
drug ingredient level (<bold>d</bold>). This table is the substrate for counting
the incidence of exposure to &#x02018;at least&#x02019; drug combinations
(<bold>e).</bold> Exposure counts for combinations of <italic>N</italic>=1
to 5 drug ingredients are published in Data Record 1. Exact drug ingredient
combinations (<bold>d</bold>) are translated to drug class combinations
(<bold>f</bold>), keeping only unique classes. Again, these are used to
count the exposure incidence of &#x02018;at least&#x02019; drug class
combinations (<bold>g</bold>). Exposure counts for combinations of
<italic>N</italic>=1 to 5 drug classes are published in Data Record 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sdata2017167-f1"/></fig><fig id="f2"><label>Figure 2</label><caption><title>Illustration of conversion of drug prescription date of service and days of
supply into discrete exposures.</title><p>(<bold>a</bold>) Shows three typical prescription patterns, converted to exposure
in three windows, using non-overlapping 30-day windows. (<bold>b</bold>) Shows
uncommon prescription patterns that introduce error in interpretation of
concomitant exposure: While A and B are separated by only a few days, and may be
considered concomitant, they are not counted as concomitant exposures; While
Drugs C and D are separated by many days, they are recorded as concomitant
exposures in Window 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sdata2017167-f2"/></fig><fig id="f3"><label>Figure 3</label><caption><title>Distributions of the number of unique concomitant drug exposures per
patient-months.</title><p>Distributions are for concomitant exposures to (<bold>a</bold>) drug ingredients
and (<bold>b</bold>) drug classes, truncated at 10, across the 3.0 billion
observed patient-months, including 1.7 billion with prescription drug exposures.
(The 43% (=1.3/3 billion) of patient-months with no drug exposures are not shown
on these plots.) Patients taking any prescription drugs are exposed to a median
of 2 and 95th-percentile of 8 drug ingredients, and a median of 2 and
95th-percentile of 7 unique drug classes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sdata2017167-f3"/></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Summary of Truven Health MarketScan Research Database prescription data and
drug combination counts.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Prescription claims database summary
statistics:</bold></th><th align="left" valign="top" charoff="50">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x02003;Number of patients</td><td align="left" valign="top" charoff="50">82 million</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median months of patient observation</td><td align="left" valign="top" charoff="50">30</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Range of months of patient observation (10% to
90%)</td><td align="left" valign="top" charoff="50">8 to 84</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Number of months of patient
observation</td><td align="left" valign="top" charoff="50">3.0 billion</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Number of months with drug exposures</td><td align="left" valign="top" charoff="50">1.7 billion</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fraction of all months of patient eligibility with
any drug exposures</td><td align="left" valign="top" charoff="50">57%</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Total number of prescription drug
claims</td><td align="left" valign="top" charoff="50">3.2 billion</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Drug combination counting summary
statistics</italic>:</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Number of discrete 30-day window drug
exposures</td><td align="left" valign="top" charoff="50">5.1 billion</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Number of unique drug ingredient
combinations</td><td align="left" valign="top" charoff="50">220 million</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fraction of windows with unique drug ingredient
exposure</td><td align="left" valign="top" charoff="50">10%</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Number unique drug class
combinations</td><td align="left" valign="top" charoff="50">39 million</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fraction of windows with unique drug class
exposure</td><td align="left" valign="top" charoff="50">2%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Data Records description.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50"><bold>Description</bold></th><th align="left" valign="top" charoff="50"><bold>File or column name</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Data Record 1: Drug ingredient combination exposure
counts</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Files</italic></td><td align="left" valign="top" charoff="50">5 files, for combinations of N=1-to-5 drug
ingredients</td><td align="left" valign="top" charoff="50"><italic>db_drugs_Ns.tsv</italic></td></tr><tr><td align="left" valign="top" charoff="50"><italic>Columns</italic></td><td align="left" valign="top" charoff="50">Drug ingredient name (N columns)</td><td align="left" valign="top" charoff="50"><italic>drug_name_A</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Count of windows with concomitant exposure to this drug
combination: potentially concomitant with additional
drugs</td><td align="left" valign="top" charoff="50"><italic>atleast_exposure_count</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Count of windows with concomitant exposure to this drug
combination and no additional drugs</td><td align="left" valign="top" charoff="50"><italic>exact_exposure_count</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Estimate of the daily cost of the drug
combination</td><td align="left" valign="top" charoff="50"><italic>estimate_drug_cost_per_day</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Fraction of exposure counts that occur with no additional
drugs (equal to the ratio of the exact to at-least exposure
counts)</td><td align="left" valign="top" charoff="50"><italic>fraction_exact</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ratio of the <italic>atleast_exposure_count</italic> to the
total number of observed windows with any prescription</td><td align="left" valign="top" charoff="50"><italic>fraction_all_windows</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ratio of the combination&#x02019;s observed to expected
incidence (<italic>atleast_exposure_count</italic>) based on
marginal frequencies of single drugs (applicable for
N&#x0003e;1).</td><td align="left" valign="top" charoff="50"><italic>observe_per_expect_1s</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ratio of the combination&#x02019;s observed to expected
incidence (<italic>atleast_exposure_count</italic>) based on
marginal frequencies of (N-1)+1 subsets (applicable for
N&#x0003e;2).</td><td align="left" valign="top" charoff="50"><italic>observe_per_expect_N1</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Data Record 2: Drug class combination exposure
counts</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Files</italic></td><td align="left" valign="top" charoff="50">5 files, for combinations of N=1-to-5 drug
classes</td><td align="left" valign="top" charoff="50"><italic>db_atc_classes_Ns.tsv</italic></td></tr><tr><td align="left" valign="top" charoff="50"><italic>Columns</italic></td><td align="left" valign="top" charoff="50">Drug class code (N columns)</td><td align="left" valign="top" charoff="50"><italic>atc_code_A</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Drug class name (N columns)</td><td align="left" valign="top" charoff="50"><italic>atc_name_A</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Count of windows with concomitant exposure to this drug
combination: potentially concomitant with additional
drugs</td><td align="left" valign="top" charoff="50"><italic>atleast_exposure_count</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Count of windows with concomitant exposure to this drug
combination and no additional drugs</td><td align="left" valign="top" charoff="50"><italic>exact_exposure_count</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Fraction of exposure counts that occur with no additional
drugs (equal to the ratio of the exact to at-least exposure
counts)</td><td align="left" valign="top" charoff="50"><italic>fraction_exact</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ratio of the <italic>atleast_exposure_count</italic> to the
total number of observed windows with any prescription</td><td align="left" valign="top" charoff="50"><italic>fraction_all_windows</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ratio of the combination&#x02019;s observed to expected
incidence (<italic>atleast_exposure_count</italic>) based on
marginal frequencies of single drugs (applicable for
N&#x0003e;1).</td><td align="left" valign="top" charoff="50"><italic>observe_per_expect_1s</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ratio of the combination&#x02019;s observed to expected
incidence (<italic>atleast_exposure_count</italic>) based on
marginal frequencies of (N-1)+1 subsets (applicable for
N&#x0003e;2).</td><td align="left" valign="top" charoff="50"><italic>observe_per_expect_N1</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Data Record 3: Drug mappings</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Files</italic></td><td align="left" valign="top" charoff="50">2 files, for the drug ingredient list and drug class
list</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>File:</italic></td><td align="left" valign="top" charoff="50">Drug ingredient mappings</td><td align="left" valign="top" charoff="50"><italic>drug_mappings_ingredients.tsv</italic></td></tr><tr><td align="left" valign="top" charoff="50"><italic>Columns</italic></td><td align="left" valign="top" charoff="50">Drug ingredient name</td><td align="left" valign="top" charoff="50"><italic>drug_name</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">RxNORM CUI number</td><td align="left" valign="top" charoff="50"><italic>rxcui</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">ATC code</td><td align="left" valign="top" charoff="50"><italic>atc_code</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Second-level ATC drug class name (redundant, provided for
convenience)</td><td align="left" valign="top" charoff="50"><italic>atc_name</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Estimated median cost per day</td><td align="left" valign="top" charoff="50"><italic>estimate_drug_cost_per_day</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">UMLS CUI</td><td align="left" valign="top" charoff="50"><italic>UMLS_CUI</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Drug Bank ID</td><td align="left" valign="top" charoff="50"><italic>DrugBankID</italic></td></tr><tr><td align="left" valign="top" charoff="50"><italic>File:</italic></td><td align="left" valign="top" charoff="50">Drug class mappings</td><td align="left" valign="top" charoff="50"><italic>drug_mappings_atc_classes.tsv</italic></td></tr><tr><td align="left" valign="top" charoff="50"><italic>Columns</italic></td><td align="left" valign="top" charoff="50">Second-level ATC code</td><td align="left" valign="top" charoff="50"><italic>atc_class</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Second-level ATC drug class name</td><td align="left" valign="top" charoff="50"><italic>atc_class_name</italic></td></tr></tbody></table></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Common 3-drug combinations most overrepresented prior to ED visits.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Rank</bold></th><th align="left" valign="top" charoff="50"><bold>Drug
combination</bold></th><th align="center" valign="top" charoff="50"><bold>Relative risk</bold></th><td>&#x000a0;</td><td>&#x000a0;</td></tr></thead><tfoot valign="top"><tr><th align="left" valign="top" charoff="50">Patients prescribed these common 3-drug combinations visit the ED at rates
approximately 3-fold higher than the general population. Overrepresentation is
calculated by comparing the incidence of 3-drug combination exposures in the
30-day window prior to ED visits (based on only the first ED visit per patient)
to their overall incidence, as recorded in Data Record 1. This table includes
only common 3-drug combinations, with greater than 5000 occurrences in the
database.</th><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td></tr></tfoot><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>1</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">oxycodone</td><td align="center" valign="top" charoff="50">prochlorperazine</td><td align="center" valign="top" char="." charoff="50">3.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>2</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">enoxaparin</td><td align="center" valign="top" charoff="50">oxycodone</td><td align="center" valign="top" char="." charoff="50">3.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>3</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">hydrocodone</td><td align="center" valign="top" charoff="50">prochlorperazine</td><td align="center" valign="top" char="." charoff="50">3.5</td></tr><tr><td align="left" valign="top" charoff="50"><bold>4</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">enoxaparin</td><td align="center" valign="top" charoff="50">warfarin</td><td align="center" valign="top" char="." charoff="50">3.5</td></tr><tr><td align="left" valign="top" charoff="50"><bold>5</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">enoxaparin</td><td align="center" valign="top" charoff="50">hydrocodone</td><td align="center" valign="top" char="." charoff="50">3.4</td></tr><tr><td align="left" valign="top" charoff="50"><bold>6</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">dexamethasone</td><td align="center" valign="top" charoff="50">oxycodone</td><td align="center" valign="top" char="." charoff="50">3.1</td></tr><tr><td align="left" valign="top" charoff="50"><bold>7</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">levofloxacin</td><td align="center" valign="top" charoff="50">oxycodone</td><td align="center" valign="top" char="." charoff="50">2.8</td></tr><tr><td align="left" valign="top" charoff="50"><bold>8</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">ciprofloxacin</td><td align="center" valign="top" charoff="50">phenazopyridine</td><td align="center" valign="top" char="." charoff="50">2.7</td></tr><tr><td align="left" valign="top" charoff="50"><bold>9</bold></td><td align="center" valign="top" charoff="50">ondansetron</td><td align="center" valign="top" charoff="50">sulfamethoxazole</td><td align="center" valign="top" charoff="50">trimethoprim</td><td align="center" valign="top" char="." charoff="50">2.7</td></tr><tr><td align="left" valign="top" charoff="50"><bold>10</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">codeine</td><td align="center" valign="top" charoff="50">sulfamethoxazole</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>11</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">levofloxacin</td><td align="center" valign="top" charoff="50">metoprolol</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>12</bold></td><td align="center" valign="top" charoff="50">levofloxacin</td><td align="center" valign="top" charoff="50">sulfamethoxazole</td><td align="center" valign="top" charoff="50">trimethoprim</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>13</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">codeine</td><td align="center" valign="top" charoff="50">trimethoprim</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>14</bold></td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" charoff="50">ciprofloxacin</td><td align="center" valign="top" charoff="50">sulfamethoxazole</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr><tr><td align="left" valign="top" charoff="50"><bold>15</bold></td><td align="center" valign="top" charoff="50">amoxicillin</td><td align="center" valign="top" charoff="50">clavulanate</td><td align="center" valign="top" charoff="50">ondansetron</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t4"><label>Table 4</label><caption><title>Summary of the most common and most overrepresented drug ingredient
co-exposures with metformin and oxycodone.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Rank</bold></th><th align="left" valign="top" charoff="50"><bold>Drug ingredient</bold></th><th align="center" valign="top" char="." charoff="50"><bold>P(co-exposure |
exposure)</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Observed/Expected
Incidence</bold></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Metformin
co-exposures, top 5, ranked by incidence:</italic><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">hydrochlorothiazide</td><td align="center" valign="top" char="." charoff="50">0.26</td><td align="center" valign="top" char="." charoff="50">2.2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">lisinopril</td><td align="center" valign="top" char="." charoff="50">0.25</td><td align="center" valign="top" char="." charoff="50">3.0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">simvastatin</td><td align="center" valign="top" char="." charoff="50">0.22</td><td align="center" valign="top" char="." charoff="50">2.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">atorvastatin</td><td align="center" valign="top" char="." charoff="50">0.15</td><td align="center" valign="top" char="." charoff="50">2.6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;5</td><td align="center" valign="top" charoff="50">amlodipine</td><td align="center" valign="top" char="." charoff="50">0.13</td><td align="center" valign="top" char="." charoff="50">2.2</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Metformin
co-exposures, top 5, ranked by
overrepresentation:</italic><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">glyburide</td><td align="center" valign="top" char="." charoff="50">0.10</td><td align="center" valign="top" char="." charoff="50">12.6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">saxagliptin</td><td align="center" valign="top" char="." charoff="50">0.02</td><td align="center" valign="top" char="." charoff="50">11.9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">sitagliptin</td><td align="center" valign="top" char="." charoff="50">0.11</td><td align="center" valign="top" char="." charoff="50">11.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">rosiglitazone</td><td align="center" valign="top" char="." charoff="50">0.03</td><td align="center" valign="top" char="." charoff="50">11.2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;5</td><td align="center" valign="top" charoff="50">dapaglifozin</td><td align="center" valign="top" char="." charoff="50">&#x0003c;0.01</td><td align="center" valign="top" char="." charoff="50">10.8</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Oxycodone
co-exposures, top 5, ranked by incidence:</italic><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">acetaminophen</td><td align="center" valign="top" char="." charoff="50">0.78</td><td align="center" valign="top" char="." charoff="50">11.1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">hydrocodone</td><td align="center" valign="top" char="." charoff="50">0.16</td><td align="center" valign="top" char="." charoff="50">3.1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">hydrochlorothiazide</td><td align="center" valign="top" char="." charoff="50">0.11</td><td align="center" valign="top" char="." charoff="50">0.9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">alprazolam</td><td align="center" valign="top" char="." charoff="50">0.10</td><td align="center" valign="top" char="." charoff="50">3.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;5</td><td align="center" valign="top" charoff="50">zolpidem</td><td align="center" valign="top" char="." charoff="50">0.09</td><td align="center" valign="top" char="." charoff="50">3.1</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Oxycodone
co-exposures, top 5, ranked by
overrepresentation:</italic><hr/></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">methylnaltrexone</td><td align="center" valign="top" char="." charoff="50">&#x0003c;0.01</td><td align="center" valign="top" char="." charoff="50">23.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">oxymorphone</td><td align="center" valign="top" char="." charoff="50">0.01</td><td align="center" valign="top" char="." charoff="50">22.1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">fentanyl</td><td align="center" valign="top" char="." charoff="50">0.04</td><td align="center" valign="top" char="." charoff="50">16.7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="center" valign="top" charoff="50">morphine</td><td align="center" valign="top" char="." charoff="50">0.04</td><td align="center" valign="top" char="." charoff="50">15.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;5</td><td align="center" valign="top" charoff="50">methadone</td><td align="center" valign="top" char="." charoff="50">0.02</td><td align="center" valign="top" char="." charoff="50">14.6</td></tr></tbody></table></table-wrap></floats-group></article>